Updates on Celcuity's VIKTORIA-1 Trial
Celcuity Inc. (NASDAQ: CELC), an innovative biotechnology firm, is gearing up for a key presentation at the upcoming SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS). This presentation is particularly significant as it will delve into the updated data from the PIK3CA wild-type cohort of their Phase 3 VIKTORIA-1 trial.
Importance of the SABCS Presentation
The SABCS, which takes place from December 9-12, will be held both virtually and in-person. Celcuity's abstract has been accepted for oral presentation, which is a testament to the importance of this research in the oncology community. The company's focus is to share additional efficacy analyses along with safety data, highlighting their commitment to advancing breast cancer treatments.
Details of the Presentation
The abstract titled "Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial" will be presented by Barbara Pistilli, MD. The specific presentation number is RF7-04 and it will take place on December 11. This session, designated as Rapid Fire 7, promises to provide critical insights into the ongoing research.
About Gedatolisib and the VIKTORIA Trials
Gedatolisib represents a breakthrough in targeted therapies, specifically designed to inhibit the PI3K/AKT/mTOR pathway. This pathway has been a focal point in cancer research due to its significant role in various solid tumors. The VIKTORIA-1 trial has already made considerable progress, completing enrollment for patients with both PIK3CA wild-type and mutant cohorts, and has provided promising results in its efficacy thus far.
The Ongoing Commitment of Celcuity
Alongside VIKTORIA-1, Celcuity is also operating a Phase 3 trial, VIKTORIA-2, that is looking to evaluate gedatolisib in combination with fulvestrant and a CDK4/6 inhibitor as a first-line treatment for HR+/HER2- ABC patients. Moreover, the company’s exploration extends into a Phase 1/2 clinical trial (CELC-G-201) which is assessing gedatolisib with darolutamide in metastatic castration-resistant prostate cancer, showcasing the broad applications of their leading therapeutic candidate.
Future Developments
Further updates from Celcuity regarding their progress in clinical trials are essential for stakeholders, as each revelation contributes to a larger understanding of the potential of gedatolisib in targeted cancer treatments. The company remains committed not just to ongoing research but to transparency with its findings as they strive towards innovations that could transform patient care.
Frequently Asked Questions
What is the VIKTORIA-1 trial?
The VIKTORIA-1 trial is a Phase 3 trial evaluating the efficacy of gedatolisib combined with fulvestrant in patients suffering from advanced breast cancer.
When will Celcuity present the VIKTORIA-1 trial data?
Celcuity will present updated data at the SABCS on December 11, during the Rapid Fire 7 session.
What is gedatolisib?
Gedatolisib is a multi-target inhibitor designed to block the PI3K/AKT/mTOR pathway, pivotal in many cancers.
How can I find more information about Celcuity's clinical trials?
Additional details about ongoing clinical trials can be accessed through ClinicalTrials.gov.
Who can I contact at Celcuity for more information?
For inquiries, you can contact Brian Sullivan at bsullivan@celcuity.com or Vicky Hahne at vhahne@celcuity.com.
